Bruker's Q2 Revenues Rise 33 Percent

Growth was fueled by demand across almost all of Bruker's end markets, and while US academic funding has been softer in comparison, it has remained "decent."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories